Abstract
Objective To assess the effects of low dose recombinant growth hormone (GH), testosterone (T) and combined GH and T, on lipid profiles and very low density lipoprotein apolipoprotein B (VLDL apoB) metabolism. Design and patients Sixty-nine healthy elderly men (65–80 yr) were studied in a six month double-blind, placebo-controlled trial. Participants were randomised to placebo GH and placebo T (P), GH and placebo T (GH), T and placebo GH (T) or GH and T (GHT). Measurements Plasma lipid profiles were assessed before treatment and at 6 months. VLDL apoB absolute secretion rate (ASR) and fractional catabolic rate (FCR) were measured in a subset of 21 men: P ( n = 5); GH ( n = 5); T ( n = 6); GHT ( n = 5), with an infusion of 1- 13C leucine. Fat mass (FM) was measured by DEXA and intra-abdominal fat (IAF) by CT scan. Results IGF-I levels increased in the GH and GHT ( P < 0.001) groups: testosterone increased in the T ( P = 0.029) and GHT ( P = 0.05) groups. There was no change in total cholesterol, LDL-cholesterol, HDL-cholesterol, triglycerides, apolipoprotein A-I, apolipoprotein B or lipoprotein(a) in the GH, GHT or T groups. In the subset of 21 men, IGF-I levels increased similarly with GH and GHT ( P < 0.01) but T levels increased only with T ( P < 0.03). FM and IAF decreased significantly only with GHT ( P < 0.01, P = 0.01). Treatment with GH, T or GHT had no effect on VLDL apoB ASR or VLDL FCR. Conclusion Co-administration of GH and T in near physiological doses in healthy elderly men resulted in favourable changes in body composition without altering the plasma lipid profile or VLDL apoB metabolism.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call